Chemotherapy-induced myelosuppression worsens fatigue and daily function, drives dose delays, and may limit future treatment options—making early management critical.
Taylor Praska, PharmD
Advertisement
Articles by Taylor Praska, PharmD
Learn how proactive myeloprotection, including trilaciclib, helps manage myelosuppression and keep chemo on track in extensive-stage SCLC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
4
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
5